Experimental shot aims to revive weak immune systems in HIV patients
NCT ID NCT07443228
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests an experimental drug called JL18008 in HIV patients whose immune systems have not fully recovered despite standard antiretroviral therapy. The study will enroll 52 adults and give them a single injection of JL18008 or a placebo. Researchers will check for side effects and measure whether the drug improves immune cell counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JL18008 (an experimental drug injection)
- What this could lead to
- If it works, this could help HIV patients with weak immune systems better fight off infections, even when standard HIV drugs are controlling the virus.
- What could go wrong
- This is a very early Phase I/II trial with only 52 people. The drug may not improve immune function, and side effects are unknown. It is not a cure for HIV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?